Vaxxinity Inc (NASDAQ:VAXX) shares, rose in value, with the stock price down by -33.70% to the previous day’s close as strong demand from buyers drove the stock to $0.13.
Actively observing the price movement in the last trading, the stock closed the session at $0.20. Referring to stock’s 52-week performance, its high was $3.10, and the low was $0.19. On the whole, VAXX has fluctuated by -80.03% over the past month.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VAXX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VAXX currently trading nearly -76.07% and -79.74% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 17.01, while the 7-day volatility ratio is showing 34.38% which for the 30-day chart, stands at 17.08%. Furthermore, Vaxxinity Inc (VAXX)’s beta value is 2.70, and its average true range (ATR) is 0.09.
A comparison of Vaxxinity Inc (VAXX) with its peers suggests the former has fared considerably weaker in the market. VAXX showed an intraday change of -33.70% in last session, and over the past year, it shrunk by -92.83%%.
Data on historical trading for Vaxxinity Inc (NASDAQ:VAXX) indicates that the trading volumes over the past 3 months, they’ve averaged 574.00K. According to company’s latest data on outstanding shares, there are 112.87 million shares outstanding.
Nearly 64.25% of Vaxxinity Inc’s shares belong to company insiders and institutional investors own 9.91% of the company’s shares. The stock has fallen by -84.40% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VAXX stock heading into the next quarter.
